Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application

29 May 2022

Abstract excerpt

In order to expand the promise of regenerative medicine using allogeneic induced pluripotent stem cells (iPSCs), precise and efficient genome editing of human leukocyte antigen (HLA) genes would be advantageous to minimize the immune rejection caused by mismatches of HLA type. However, clinical-grade genome editing of multiple HLA genes in human iPSC lines remains unexplored. Here, we optimized the protocol for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to CRISPR and Genetic Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35755947
DOI: 10.1016/j.omtm.2022.05.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical applicationPMID 35755947Read ↗

Generation of hypoimmunogenic universal iPSCs through HLA-type gene knockoutSemantic proximity Read ↗

Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative MedicineSemantic proximity Read ↗

CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2)Semantic proximity Read ↗

Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editingSemantic proximity Read ↗

Current status and future perspectives of HLA-edited induced pluripotent stem cellsSemantic proximity Read ↗

Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockoutSemantic proximity Read ↗

Generation of universal and hypoimmunogenic human pluripotent stem cellsSemantic proximity Read ↗

Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune CompatibilitySemantic proximity Read ↗

Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies.Semantic proximity Read ↗

Generation of hypoimmunogenic human pluripotent stem cellsSemantic proximity Read ↗

B2M gene knockout in HEK293T cells by non-viral delivery of CRISPR-Cas9 for the induction of universal cellSemantic proximity Read ↗

Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.